Aim: To study potential factors associated with improved glycemic control in PWT1D switching from QD or twice-daily (BID) basal insulin (BI) to QD Gla-300.
Methods: Data from PWT1D in the European REALI pooled database who switched to Gla-300 were analyzed by multivariable ANCOVA to determine factors related to HbA1c change from baseline (BL) to 6 months (6 M) post-treatment. Variables with p<0.10 in the final model were retained.
Results: A total of 455 PWT1D (TOUJEO-NEO, N=397; OPTIMIZE, N=58) were pooled, of whom 436 received Gla-300. Mean age was 50.0±14.7 years and median (Q1, Q3) diabetes duration was 18.0 (10.0, 27.0) years. Almost half of PWT1D (47.3%) presented with ≥1 cardiovascular disease/risk factor and 16.7% with diabetes complications. Mean±SD BL HbA1c was 8.3±0.84%; and change from BL to 6 M was -0.43±0.81%. A total of 179/427 (41.9%) PWT1D received BID BI, 39.1% used Gla-100, and overall mean±SD BI dose was 30.4±17.8 U/day. High BL HbA1c (p<0.0001), prior non-insulin glucose-lowering agent (p=0.027), and absence of diabetes complications (p=0.058) were associated with greater reductions in HbA1c, but not prior BID BI regimen (Table).
Conclusion: Likelihood of achieving clinically important HbA1c reduction in PWT1D switched to QD Gla-300 was mostly dependent on BL HbA1c, and not on previous BID BI regimen.
D. Müller-wieland: Advisory Panel; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, MSD Corporation, Novo Nordisk, Sanofi, Consultant; Self; Bayer AG, Speaker’s Bureau; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, MSD Corporation, Novo Nordisk, Sanofi. P. Gourdy: Advisory Panel; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Mundipharma International, Novo Nordisk, Sanofi, Research Support; Self; Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company, Sanofi. R. C. Bonadonna: Advisory Panel; Self; Sanofi, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company. N. Freemantle: Consultant; Self; AstraZeneca, Research Support; Self; ALK, Altimmune, Ipsen Biopharmaceuticals, Inc., Sanofi, Speaker’s Bureau; Self; Novo Nordisk. G. Bigot: None. C. Jamoul: None. A. Ciocca: Employee; Self; Sanofi. M. Bonnemaire: Employee; Self; Sanofi. D. Mauricio: None.